Mefitel film for radiation dermatitis: it works, why not?

Published Date: 13 Mar 2023

According to the results of a phase 3 trial, the use of silicone film before radiotherapy can reduce the incidence of radiodermatitis, so why not use it?

Read Full News

Latest News

TYK2 inhibitor Promising for Psoriasis in Phase 3 Studies

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety concerns emerging.

EU Backs Targeted BRAF Combo in Melanoma, Thyroid Cancer

European authorities have backed a targeted BRAF/MEK inhibitor combo for radioactive iodine-refractory thyroid cancer and extended its use to adolescents with advanced or resected melanoma.

Incyte's Skin Disease Drug Shows Long-term Symptom Relief in Late-stage Trials

Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in ⁠two late-stage trials.

Superficial Radiation Tx Costs Exceed Mohs Surgery for NMSC

Image-guided superficial radiation therapy remains a higher-cost treatment than Mohs surgery for nonmelanoma skin cancer, a retrospective study shows.

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Todays Updates

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Todays Updates

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Latest News

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety concerns emerging.

European authorities have backed a targeted BRAF/MEK inhibitor combo for radioactive iodine-refractory thyroid cancer and extended its use to adolescents with advanced or resected melanoma.

Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in ⁠two late-stage trials.

Image-guided superficial radiation therapy remains a higher-cost treatment than Mohs surgery for nonmelanoma skin cancer, a retrospective study shows.

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

News All Time

Exclusive-Child Vaccination Rate Drops Sharply in Michigan as RFK Jr Influences Policy

Vaccination rates among young children in Michigan dropped sharply during the first year of the Trump administration, a Reuters analysis of state data shows, providing an...

FDA Approves Icotrokinra for Moderate-to-Severe Psoriasis

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Lutikizumab Offers Relief for Refractory HS

Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in a phase 2 study.

Novo Nordisk Patent Expiry Opens Door to Cheaper Weight-Loss Drugs in India

India’s diabetes and weight-loss drug market faces a shake-up as Novo Nordisk’s semaglutide patent expires, opening the door to cheaper generics.

FDA OKs Linerixibat for Cholestatic Pruritus

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Distinct Comorbidity Pattern Hinders Remission in Lupus

Patients with lupus face a high burden of comorbidities, with the presence of at least one of seven key conditions linked to 55%-60% lower odds of achieving remission or a low disease activity state.

Children With Autism Face Growing Unmet Healthcare Needs

A cross-sectional study examines annual trends in unmet healthcare needs among over 8000 children with autism.

HSV-1 May Be Increasing in Infants

A new study suggests that HSV-1 has become the dominant subtype among newborns.

Secukinumab Gets FDA Nod for Adolescent HS

Weight-based injectable’s approval is based in part on other pediatric indications.

Low-Beta Radiation Patch Offers Alternative NMSC Treatment

Similar to brachytherapy, OncoPatch could be an option for patients who have superficial lesions or who aren’t surgical candidates.

What Does FDA Food Pyramid Mean for Cancer Risk and Care?

Much of the new FDA food guidance aligns with existing advice, but some areas may introduce confusion to advising patients on diet and cancer prevention and survival.

UK Approves New JAK Inhibitor for Severe Alopecia

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on NHS access.

Tildrakizumab Now Under FDA Review for Psoriatic Arthritis

Full results from the pivotal trials submitted to support approval have not yet been reported.

Early Intensive Therapy Best for PsA With Poor Prognosis

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes were maintained at 48 weeks in the TNFi group.

Guselkumab Effective After TNF Inhibitor Failure in PsA

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Meta-analysis: Dermoscopic Features Distinguish ALM

Parallel ridge and multicomponent patterns are the most common dermoscopic features that identify acral lentiginous melanoma, according to a meta-analysis.

Recommended News For You

The diamonds that could find cancer

Two medications might work better for breast cancers that are resistant to one.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

Investigations may result in novel combination therapies for early-stage lung cancers.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

Surgeons are at higher risk of cancer, study suggests

Recommended Articles For You

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide 

Subchorionic Hematoma: Causes, Symptoms, and Treatment  

Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology 

IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High levels of traumatic stress found in caregivers of adult cancer patients

2.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

3.

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.

4.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

5.

In a recent study, Kencur ginger's anti-cancer properties were discovered.

1.

The Different Types of Cysts and Why They Occur: Insights from a Dermatologist 

2.

Understanding Dasatinib: A Promising Drug for Cancer Treatment 

3.

TAR-200 in Bladder Cancer: Precision Drug Delivery Driving Oncology Advances

4.

Case Study: The Role of Machine Learning in the Detection of Skin Cancer

5.

Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

3.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

5.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot